ARGX ▼ -0.2% - argenx SE
$ARGX - argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease
08-OCT-2026 01:00 AM ET
Share this post
More filings for $ARGX
ARGX ▲ +2.0% - argenx SEOct 22, 2026ARGX ▼ -0.4% - argenx SEOct 19, 2026ARGX ▼ -0.2% - argenx SEOct 8, 2026ARGX ▼ -0.1% - argenx SESep 29, 2026ARGX ▲ +1.1% - argenx SESep 17, 2026ARGX ▲ +0.8% - argenx SESep 1, 2026
View full $ARGX filing history →💬 Comments
Loading comments…
Leave a comment